Italiano, A.; Nanda, S.; Briggs, A.; Garcia-Foncillas, J.; Lassen, U.; Vassal, G.; Kummar, S.; van Tilburg, C.M.; Hong, D.S.; Laetsch, T.W.;
et al. Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis. Cancers 2020, 12, 3246.
https://doi.org/10.3390/cancers12113246
AMA Style
Italiano A, Nanda S, Briggs A, Garcia-Foncillas J, Lassen U, Vassal G, Kummar S, van Tilburg CM, Hong DS, Laetsch TW,
et al. Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis. Cancers. 2020; 12(11):3246.
https://doi.org/10.3390/cancers12113246
Chicago/Turabian Style
Italiano, Antoine, Shivani Nanda, Andrew Briggs, Jesus Garcia-Foncillas, Ulrik Lassen, Gilles Vassal, Shivaani Kummar, Cornelis M. van Tilburg, David S. Hong, Theodore W. Laetsch,
and et al. 2020. "Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis" Cancers 12, no. 11: 3246.
https://doi.org/10.3390/cancers12113246
APA Style
Italiano, A., Nanda, S., Briggs, A., Garcia-Foncillas, J., Lassen, U., Vassal, G., Kummar, S., van Tilburg, C. M., Hong, D. S., Laetsch, T. W., Keating, K., Reeves, J. A., Fellous, M., Childs, B. H., Drilon, A., & Hyman, D. M.
(2020). Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis. Cancers, 12(11), 3246.
https://doi.org/10.3390/cancers12113246
